Biotectix, LLC Announces Research-Collaboration Agreement
21-Oct-2008
Unique Bioactive, Electrically-Conductive Materials and Nanotechnology Coatings to Improve Performance
Boston, Massachusetts -- Biotectix, LLC today announced that it entered into a strategic Research-Collaboration Agreement with a recognized global leader in implantable auditory medical devices. Biotectix will develop and demonstrate processes to apply several of its technologies and polymeric solutions to electrodes of the partner’s products and optimize the technology to work with the partner’s devices. All work is based on Biotectix’s proprietary technology and methods on bioactive, electrically conductive biomaterials that improve the biological integration and stability of implantable biomedical devices.
“We are excited to announce this strategic partnership with a market leader and innovator of such renown. Our agreement testifies to the belief in the commercial viability of our technology, our focus, and in Biotectix as a company,”commented Jorge de Dios, CEO of Biotectix. “We are confident that Biotectix’s materials will dramatically improve the performance and biocompatibility of our partner’s implantable medical devices, solve critical challenges that all implantable devices invariably face, and significantly build commercial advantages,” added Marc Eichenberger, Chief Operating Officer of Allied Minds, parent company of Biotectix.
Details of their Agreement were not disclosed.
About Biotectix, LLC
Biotectix is an innovator in developing bioactive, electrically conductive biomaterials and coatings that improve the safety, longevity, reliability, biological integration, and function of implantable biomedical devices. Biotectix’s novel proprietary biomaterials are based on soft, bioactive, conductive polymers that can join conductive systems ionically and electronically and exhibit low magnetic resonance. They also offer proprietary drug delivery capabilities and can deliver biological or pharmaceutical agents passively or on demand to prevent infection and direct tissue reaction directly at the electrode site. In addition to addressing the most vexing problems facing a wide range of implantable biomedical devices, the Biotectix technology platform introduces new paradigms that make it possible to design a new generation of electrodes and resultant devices utilizing 100% -polymer electrodes that may be grown in the body.
The Company has been funded by Allied Minds, Inc., a private investment corporation. For more information, please visit www.biotectix.com
About Allied Minds, Inc.
Allied Minds is a seed investment company creating partnerships with select universities to fund corporate spin-offs resulting from successful early stage technology research. By providing corporate development support as well as funding, Allied Minds aims to guide early stage companies to commercial success, thereby generating value for all stakeholders. For more information, logon to www.alliedminds.com
For additional information contact;
Jorge de Dios, CEO
Biotectix LLC, an Allied Minds Company
(703) 338-3361
jorge.dedios@alliedminds.com
